The Meloni government is advancing a long-awaited overhaul of pharmaceutical legislation, presenting it as a tool to boost competitiveness, accelerate innovation and attract investment. For Rome, the pharmaceutical sector is no longer viewed solely through the lens of healthcare, but as a strategic asset linked to technological sovereignty, economic resilience and national autonomy.
The Meloni government is advancing a long-awaited overhaul of pharmaceutical legislation, presenting it as a tool to boost competitiveness, accelerate innovation and attract investment. For Rome, the pharmaceutical sector is no longer viewed solely...
As EU leaders met in Brussels on June 18-19 for a two-day European Council summit, discussions on Ukraine, European defence and the next EU budget highlighted issues...
Italy could soon join Pax Silica, the US-led initiative designed to secure the supply chains underpinning artificial intelligence and other strategic technologies. The...
For Kaush Arha, former senior advisor at the U.S. Department of State and a longtime expert on American foreign policy, the public dispute between Giorgia Meloni and Donald Trump is unlikely to cause lasting damage to U.S.-Italy relations. On the...
While public attention remains focused on the Trump-Meloni dispute, two U.S. experts and former officials, Carla Sands and Alexander Gray, argue that the future of U.S...
Donald Trump’s latest criticism of Italy goes beyond his public exchange with Giorgia Meloni. According to Elisa Catalano Ewers, the episode reflects both a familiar...
